RU2021257C1 - Способ получения водного раствора изетионата пентамидина - Google Patents
Способ получения водного раствора изетионата пентамидина Download PDFInfo
- Publication number
- RU2021257C1 RU2021257C1 SU904743178A SU4743178A RU2021257C1 RU 2021257 C1 RU2021257 C1 RU 2021257C1 SU 904743178 A SU904743178 A SU 904743178A SU 4743178 A SU4743178 A SU 4743178A RU 2021257 C1 RU2021257 C1 RU 2021257C1
- Authority
- RU
- Russia
- Prior art keywords
- pentamidine
- aqueous solution
- solution
- isethionate
- pentamidine isethionate
- Prior art date
Links
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 9
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 title claims description 25
- 238000000034 method Methods 0.000 title claims description 4
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 239000008351 acetate buffer Substances 0.000 claims abstract description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229960001624 pentamidine isethionate Drugs 0.000 claims description 23
- 229960004448 pentamidine Drugs 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 150000005846 sugar alcohols Chemical class 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 5
- 235000001727 glucose Nutrition 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005695 Ammonium acetate Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229940043376 ammonium acetate Drugs 0.000 claims description 2
- 235000019257 ammonium acetate Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical class C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 239000000243 solution Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960000673 dextrose monohydrate Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- QKRMFCXDTFLKKT-UHFFFAOYSA-N 2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O QKRMFCXDTFLKKT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000654 trypanocidal effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
- Confectionery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898903438A GB8903438D0 (en) | 1989-02-15 | 1989-02-15 | New compositions of matter |
| GB8922707.8 | 1989-10-09 | ||
| GB898922707A GB8922707D0 (en) | 1989-02-15 | 1989-10-09 | New compositions of matter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021257C1 true RU2021257C1 (ru) | 1994-10-15 |
Family
ID=10651746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU904743178A RU2021257C1 (ru) | 1989-02-15 | 1990-02-14 | Способ получения водного раствора изетионата пентамидина |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5089527A (enExample) |
| EP (1) | EP0383680B1 (enExample) |
| JP (1) | JP2835123B2 (enExample) |
| KR (1) | KR0156929B1 (enExample) |
| AT (1) | ATE83656T1 (enExample) |
| AU (1) | AU637997B2 (enExample) |
| CA (1) | CA2010085C (enExample) |
| DD (1) | DD291924A5 (enExample) |
| DE (1) | DE69000621T2 (enExample) |
| DK (1) | DK0383680T3 (enExample) |
| ES (1) | ES2054281T3 (enExample) |
| FI (1) | FI92147C (enExample) |
| GB (2) | GB8903438D0 (enExample) |
| GR (1) | GR3006654T3 (enExample) |
| HU (1) | HU208071B (enExample) |
| IE (1) | IE63090B1 (enExample) |
| IL (1) | IL93371A (enExample) |
| NO (1) | NO175734C (enExample) |
| NZ (1) | NZ232511A (enExample) |
| PT (1) | PT93154B (enExample) |
| RU (1) | RU2021257C1 (enExample) |
| YU (1) | YU47341B (enExample) |
| ZA (1) | ZA901087B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2180206A1 (en) * | 1995-06-30 | 1996-12-31 | Motoya Ohshika | Freeze-dried preparation for pharmaceutical use |
| DK1231910T3 (da) * | 1999-11-16 | 2009-08-31 | Oncozyme Pharma Inc | Pentamidin til behandling af cancer |
| US7115665B1 (en) | 2000-11-16 | 2006-10-03 | Onocozyme Pharma, Inc. | Inhibitors of endo-exonuclease activity for treating cancer |
| CA2559208A1 (en) * | 2004-03-17 | 2005-09-29 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
| US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59140636U (ja) * | 1983-03-11 | 1984-09-20 | 株式会社日本アルミ | 内装材 |
| JPS61120841U (enExample) * | 1985-01-16 | 1986-07-30 | ||
| US4696812A (en) * | 1985-10-28 | 1987-09-29 | Warner-Lambert Company | Thrombin preparations |
| AU620025B2 (en) * | 1987-03-26 | 1992-02-13 | Sloan-Kettering Institute For Cancer Research | Method of preventing pneumocystis carinii pneumonia using pentamidine in an aerosol form |
| IN168530B (enExample) * | 1987-11-06 | 1991-04-20 | Lyphomed Inc | |
| US4853416A (en) * | 1988-04-25 | 1989-08-01 | Fisons Corporation | Solutions of pentamidine |
-
1989
- 1989-02-15 GB GB898903438A patent/GB8903438D0/en active Pending
- 1989-10-09 GB GB898922707A patent/GB8922707D0/en active Pending
-
1990
- 1990-02-12 US US07/478,488 patent/US5089527A/en not_active Expired - Lifetime
- 1990-02-12 YU YU26790A patent/YU47341B/sh unknown
- 1990-02-13 ZA ZA901087A patent/ZA901087B/xx unknown
- 1990-02-13 AU AU49354/90A patent/AU637997B2/en not_active Expired
- 1990-02-13 IE IE51290A patent/IE63090B1/en not_active IP Right Cessation
- 1990-02-13 IL IL9337190A patent/IL93371A/en not_active IP Right Cessation
- 1990-02-13 NZ NZ232511A patent/NZ232511A/xx unknown
- 1990-02-13 KR KR1019900001763A patent/KR0156929B1/ko not_active Expired - Fee Related
- 1990-02-13 JP JP2029775A patent/JP2835123B2/ja not_active Expired - Lifetime
- 1990-02-14 ES ES90400398T patent/ES2054281T3/es not_active Expired - Lifetime
- 1990-02-14 DE DE9090400398T patent/DE69000621T2/de not_active Expired - Lifetime
- 1990-02-14 FI FI900727A patent/FI92147C/fi active IP Right Grant
- 1990-02-14 DD DD90337851A patent/DD291924A5/de not_active IP Right Cessation
- 1990-02-14 EP EP90400398A patent/EP0383680B1/en not_active Expired - Lifetime
- 1990-02-14 DK DK90400398.5T patent/DK0383680T3/da active
- 1990-02-14 RU SU904743178A patent/RU2021257C1/ru active
- 1990-02-14 NO NO900706A patent/NO175734C/no not_active IP Right Cessation
- 1990-02-14 CA CA002010085A patent/CA2010085C/en not_active Expired - Lifetime
- 1990-02-14 HU HU90804A patent/HU208071B/hu unknown
- 1990-02-14 AT AT90400398T patent/ATE83656T1/de not_active IP Right Cessation
- 1990-02-15 PT PT93154A patent/PT93154B/pt active IP Right Grant
-
1992
- 1992-12-24 GR GR920401767T patent/GR3006654T3/el unknown
Non-Patent Citations (1)
| Title |
|---|
| ЕР N 345926, кл. A 61K 31/155, 1989. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4153689A (en) | Stable insulin preparation for nasal administration | |
| RU2016567C1 (ru) | Способ получения средства, обладающего противовирусным действием | |
| RU2260429C9 (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
| EA001903B1 (ru) | Интраназальные композиции для лечения сексуальных расстройств | |
| EA006068B1 (ru) | Оптимизированный препарат тобрамицина для аэрозолизации | |
| US20200316003A1 (en) | Fudosteine Solution Preparation for Aerosol Inhalation, and Preparation Method Therefor | |
| US20250302779A1 (en) | Stable aqueous hydroxycarbamide solution | |
| US20050158247A1 (en) | Nasal peptide pharmaceutical formulation | |
| RU2367442C2 (ru) | Способ нормализации мочеиспускания при нарушении функции почек | |
| US20220016054A1 (en) | Epinephrine parenteral formulations | |
| EP0345926B1 (en) | Pharmaceutical compositions containing pentamidine | |
| GB2564444A (en) | Liquid pharmaceutical composition of flecainide | |
| US3629425A (en) | Stabilized 2-pam solutions | |
| US3275513A (en) | Stable calcium tetracycline compositions | |
| US5089527A (en) | Pentamidine solutions | |
| EP0338670B1 (en) | Pharmaceutical Compositions | |
| HK1245116A1 (zh) | 液体胰岛素制剂及与其相关的方法 | |
| WO2024227895A2 (en) | Oral solution comprising liothyronine sodium | |
| SK3322003A3 (en) | Infusion of ciprofloxacin having reduced acid content and being stable in storage | |
| JP3034949B2 (ja) | 医薬製剤 | |
| US4406888A (en) | Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution | |
| JP3462399B2 (ja) | 塩酸ニカルジピン含有液剤 | |
| BG1842U1 (bg) | Фармацевтичен състав на разтвор за перорални капки, съдържащ метамизол | |
| US20260130849A1 (en) | Edaravone Oral Solution Compositions | |
| EP0662828A1 (en) | Trimethoprim oral liquid |